Browse Studies — Arctuva

Phase 2

A Phase IIa Clinical Trial of First-Line Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for Advanced Biliary Tract Cancers With FGFR2 Alterations

This phase II trial tests how well giving gemcitabine, cisplatin and durvalumab alternating with pemigatinib for the treatment of biliary tract cancer with FGF…

Locally Advanced Ampulla of Vater CarcinomaLocally Advanced Biliary Tract CarcinomaLocally Advanced Extrahepatic Cholangiocarcinoma+20 more

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07780838

Phase 2

A Phase II Trial of Durvalumab With Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high…

Resectable Intrahepatic Cholangiocarcinoma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06050252

Phase 1

MC1641 Phase II Study Of Intratumoral Injection Of Autologous Dendritic Cells Combined With Immune Checkpoint Inhibition After High-Dose Conformal External Beam Radiotherapy In Patients With Unresectable Primary Liver Cancer

This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (…

Stage III Hepatocellular Carcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+3 more

Estimated

~$10 – $6,250

Mayo ClinicNCT03942328

Phase 1

Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination With Tremelimumab Plus Durvalumab (MEDI4736) in Patients With Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)

This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in tre…

Locally Advanced Intrahepatic CholangiocarcinomaOligometastatic Intrahepatic CholangiocarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8+2 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06058663

Phase 2

Phase II, Open Label, Non-Randomized, Study of Optimal Preoperative Therapy for Intrahepatic Cholangiocarcinoma (OPTIC)

This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or wi…

Resectable Intrahepatic Cholangiocarcinoma

Estimated

~$10 – $6,250

Northwestern UniversityNCT07639528